Literature DB >> 22435959

Recognizing pitfalls in virtual screening: a critical review.

Thomas Scior1, Andreas Bender, Gary Tresadern, José L Medina-Franco, Karina Martínez-Mayorga, Thierry Langer, Karina Cuanalo-Contreras, Dimitris K Agrafiotis.   

Abstract

The aim of virtual screening (VS) is to identify bioactive compounds through computational means, by employing knowledge about the protein target (structure-based VS) or known bioactive ligands (ligand-based VS). In VS, a large number of molecules are ranked according to their likelihood to be bioactive compounds, with the aim to enrich the top fraction of the resulting list (which can be tested in bioassays afterward). At its core, VS attempts to improve the odds of identifying bioactive molecules by maximizing the true positive rate, that is, by ranking the truly active molecules as high as possible (and, correspondingly, the truly inactive ones as low as possible). In choosing the right approach, the researcher is faced with many questions: where does the optimal balance between efficiency and accuracy lie when evaluating a particular algorithm; do some methods perform better than others and in what particular situations; and what do retrospective results tell us about the prospective utility of a particular method? Given the multitude of settings, parameters, and data sets the practitioner can choose from, there are many pitfalls that lurk along the way which might render VS less efficient or downright useless. This review attempts to catalogue published and unpublished problems, shortcomings, failures, and technical traps of VS methods with the aim to avoid pitfalls by making the user aware of them in the first place.

Mesh:

Substances:

Year:  2012        PMID: 22435959     DOI: 10.1021/ci200528d

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  89 in total

1.  Ultrafast protein structure-based virtual screening with Panther.

Authors:  Sanna P Niinivehmas; Kari Salokas; Sakari Lätti; Hannu Raunio; Olli T Pentikäinen
Journal:  J Comput Aided Mol Des       Date:  2015-09-25       Impact factor: 3.686

2.  Molecular dynamics to enhance structure-based virtual screening on cathepsin B.

Authors:  Mitja Ogrizek; Samo Turk; Samo Lešnik; Izidor Sosič; Milan Hodošček; Bojana Mirković; Janko Kos; Dušanka Janežič; Stanislav Gobec; Janez Konc
Journal:  J Comput Aided Mol Des       Date:  2015-05-07       Impact factor: 3.686

3.  A facile consensus ranking approach enhances virtual screening robustness and identifies a cell-active DYRK1α inhibitor.

Authors:  Maria E Mavrogeni; Filippos Pronios; Danae Zareifi; Sofia Vasilakaki; Olivier Lozach; Leonidas Alexopoulos; Laurent Meijer; Vassilios Myrianthopoulos; Emmanuel Mikros
Journal:  Future Med Chem       Date:  2018-10-16       Impact factor: 3.808

4.  Discovery of Mer kinase inhibitors by virtual screening using Structural Protein-Ligand Interaction Fingerprints.

Authors:  C Da; M Stashko; C Jayakody; X Wang; W Janzen; S Frye; D Kireev
Journal:  Bioorg Med Chem       Date:  2015-01-13       Impact factor: 3.641

Review 5.  Shifting from the single to the multitarget paradigm in drug discovery.

Authors:  José L Medina-Franco; Marc A Giulianotti; Gregory S Welmaker; Richard A Houghten
Journal:  Drug Discov Today       Date:  2013-01-20       Impact factor: 7.851

Review 6.  Entropy-enthalpy compensation: role and ramifications in biomolecular ligand recognition and design.

Authors:  John D Chodera; David L Mobley
Journal:  Annu Rev Biophys       Date:  2013       Impact factor: 12.981

7.  The Development of Target-Specific Pose Filter Ensembles To Boost Ligand Enrichment for Structure-Based Virtual Screening.

Authors:  Jie Xia; Jui-Hua Hsieh; Huabin Hu; Song Wu; Xiang Simon Wang
Journal:  J Chem Inf Model       Date:  2017-06-01       Impact factor: 4.956

8.  Docking challenge: protein sampling and molecular docking performance.

Authors:  Khaled M Elokely; Robert J Doerksen
Journal:  J Chem Inf Model       Date:  2013-04-15       Impact factor: 4.956

9.  Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A.

Authors:  Saedeh Dadgar; Zack Ramjan; Wely B Floriano
Journal:  J Med Chem       Date:  2013-03-29       Impact factor: 7.446

Review 10.  Getting the most out of PubChem for virtual screening.

Authors:  Sunghwan Kim
Journal:  Expert Opin Drug Discov       Date:  2016-08-05       Impact factor: 6.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.